ArticleTranslational cancer research2026
Glaucocalyxin A sensitizes ovarian cancer cells to PARP inhibitors by inducing DNA damage.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Poly (ADP-ribose) polymerase inhibitors (PARPi) have demonstrated therapeutic advantages in ovarian cancer (OC) patients with homologous recombination (HR) deficiency. However, their effectiveness is limited in HR-proficient or acquired resistance tumors. Glaucocalyxin A (GLA) is an ent-kauranoid diterpene with anti-tumor properties. This study aimed to investigate the role and underlying mechanisms of GLA in OC and its potential as a sensitizing agent for PARPi. Methods: The anti-proliferative effect of GLA on OC cells was evaluated both Results: GLA significantly inhibited OC cell proliferation Conclusions: This study identifies GLA as a potential PARPi-sensitizing agent and provides a preclinical rationale for sequential combination therapy to broaden the therapeutic utility of PARPi in HR-proficient OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.